Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Alliance Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Alliance Pharma wird ein jährliches Wachstum der Erträge und Einnahmen um 46.4% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 57.7% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.8% betragen.

Wichtige Informationen

47.8%

Wachstumsrate der Gewinne

58.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	14.1%
Wachstumsrate der Einnahmen	6.3%
Zukünftige Eigenkapitalrendite	7.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Mar 24

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Sep 30

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

May 28

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Mar 30

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Dec 24

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Nov 19

Gewinn- und Umsatzwachstumsprognosen

AIM:APH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	221	30	N/A	N/A	3
12/31/2025	209	22	30	38	6
12/31/2024	196	18	29	35	6
12/31/2023	183	17	23	28	6
6/30/2023	170	-7	29	29	N/A
3/31/2023	169	-3	25	25	N/A
12/31/2022	167	1	20	21	N/A
9/30/2022	165	7	26	27	N/A
6/30/2022	163	12	32	34	N/A
3/31/2022	163	10	33	36	N/A
12/31/2021	163	7	34	39	N/A
9/30/2021	155	13	34	39	N/A
6/30/2021	147	18	34	39	N/A
3/31/2021	138	13	36	40	N/A
12/31/2020	130	8	38	42	N/A
9/30/2020	131	10	33	37	N/A
6/30/2020	131	11	29	32	N/A
3/31/2020	133	18	30	34	N/A
12/31/2019	136	25	32	36	N/A
9/30/2019	133	23	28	32	N/A
6/30/2019	130	21	24	27	N/A
3/31/2019	124	20	21	25	N/A
12/31/2018	118	18	19	22	N/A
9/30/2018	112	21	22	24	N/A
6/30/2018	107	24	24	26	N/A
3/31/2018	104	27	24	27	N/A
12/31/2017	102	29	24	27	N/A
9/30/2017	101	25	24	27	N/A
6/30/2017	100	22	24	26	N/A
3/31/2017	99	20	N/A	22	N/A
12/31/2016	97	18	N/A	17	N/A
9/30/2016	85	18	N/A	13	N/A
6/30/2016	72	18	N/A	9	N/A
3/31/2016	60	15	N/A	9	N/A
12/31/2015	48	13	N/A	8	N/A
9/30/2015	47	11	N/A	9	N/A
6/30/2015	45	8	N/A	9	N/A
3/31/2015	44	8	N/A	10	N/A
12/31/2014	44	8	N/A	11	N/A
9/30/2014	44	8	N/A	11	N/A
6/30/2014	44	9	N/A	10	N/A
3/31/2014	45	9	N/A	10	N/A
12/31/2013	45	10	N/A	9	N/A
9/30/2013	45	10	N/A	10	N/A
6/30/2013	46	10	N/A	11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: APH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.6%).

Ertrag vs. Markt: APH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: APH wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: APHDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.7% pro Jahr).

Hohe Wachstumseinnahmen: APHDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: APHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.8%).

Alliance Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.9% to UK£0.75

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 11%

Recent updates

Alliance Pharma plc Announces CEO Changes

Alliance Pharma plc to Report Fiscal Year 2023 Results on Apr 09, 2024

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Alliance Pharma plc Announces Board Changes

Price target decreased by 7.9% to UK£0.75

High number of new directors

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Alliance Pharma plc Announces Appointment of Non-Executive Directors

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc to Report First Half, 2023 Results on Sep 26, 2023

Upcoming dividend of UK£0.012 per share at 3.1% yield

Consensus EPS estimates fall by 13%

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 11%

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased by 9.1% to UK£0.92

Alliance Pharma plc Appoints Martin Sutherland as Non-Executive Director

Price target decreased to UK£0.97

Alliance Pharma plc to Report Fiscal Year 2022 Final Results on Mar 21, 2023

Alliance Pharma plc Announces Executive Changes

Logistics Development Group plc acquired a 2.38% stake in Alliance Pharma plc for £5.9 million.

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 17%

Alliance Pharma plc Announces CEO Changes

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Alliance Pharma plc Announces Revenue Guidance for Second Half of 2022

Upcoming dividend of UK£0.011 per share

Alliance Pharma plc Announces Directorate Changes

Alliance Pharma plc to Report First Half, 2022 Results on Sep 20, 2022

Alliance Pharma plc, Annual General Meeting, May 18, 2022

Alliance Pharma plc, Annual General Meeting, May 18, 2022

Insufficient new directors

Price target increased to UK£1.25

Price target increased to UK£1.20

First half 2021 earnings released: EPS UK£0.015 (vs UK£0.003 loss in 1H 2020)

Upcoming dividend of UK£0.011 per share

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Alliance Pharma plc Provides Earnings Guidance for the Full Year of 2021

Independent Non-Executive Director has left the company

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Full year 2020 earnings released: EPS UK£0.015 (vs UK£0.048 in FY 2019)

Price target lowered to UK£1.11

Alliance Pharma plc, Annual General Meeting, May 19, 2021

Price target raised to UK£1.00

Alliance Pharma plc (AIM:APH) acquired Biogix, Inc. for $110 million.

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

New 90-day high: UK£0.79

New 90-day high: UK£0.77

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

New 90-day high: UK£0.76

Analysts update estimates

First half earnings released

New 90-day high - UK£0.77

Alliance Pharma plc to Report First Half, 2020 Results on Sep 22, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken